Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-05-30
2006-05-30
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S093100, C424S093200, C424S093600, C424S130100, C424S134100, C424S141100, C424S152100, C435S005000, C435S006120, C435S007100, C435S455000, C435S456000, C435S457000, C435S325000, C435S366000, C435S320100, C514S002600, C514S04400A, C536S023100, C536S023500
Reexamination Certificate
active
07052692
ABSTRACT:
The present invention identifies a protein, designated the D-sequence-binding protein (D-BP), is phosphorylated at tyrosine residues and blocks AAV-mediated transgene expression in infected cells by inhibiting the leading strand viral DNA synthesis. More particularly, the present invention demonstrates that D-BP is phosphorylated by EGF-R protein tyrosine kinase. Methods of increasing transcription and promoting replication of transgenes exploiting this information are disclosed herein.
REFERENCES:
patent: 4933294 (1990-06-01), Waterfield et al.
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5378809 (1995-01-01), Di Fiore et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5487979 (1996-01-01), Di Fiore et al.
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5610018 (1997-03-01), Di Fiore et al.
patent: 5610288 (1997-03-01), Rubenstein
patent: 5614488 (1997-03-01), Bacha
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5674753 (1997-10-01), Harvey et al.
patent: 5679683 (1997-10-01), Bridges et al.
patent: 5708156 (1998-01-01), Ilekis
patent: 5717067 (1998-02-01), Di Fiore et al.
Ross et al., Human Gene Therapy, vol. 7, pp. 1781-1790, Sep. 10, 1996.
Kmiec, American Scientist, vol. 87, pp. 240-247, May 1999.
Verma et al., Nature, vol. 389, pp. 239-242, Sep. 18, 1997.
W. French Anderson, Nature, vol. 392, pp. 25-20, Apr. 30, 1998.
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, Dec. 7, 1995.
R.G. Crystal, Science, vol. 270, pp. 404-410, Oct. 1995.
J.L. Fox, Nature Biotechnology, vol. 18, pp. 143-144, Feb. 2000.
Barnes and Peterson, “Biochemical targets of the isoflavone genistein in tumor cell lines”,Soc. Exp. Biol. Med., 280:103-108, 1995.
Carter, “Adeno-associated virus vectors”,Curr. Opin. Biotechnol., 3:533-539, 1992.
Flotte and Carter, “Adeno-associated virus vectors for gene therapy”,Gene Ther., 2:357-362, 1995.
Kearns et al., “Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line, ”Gene Ther., 3:748-755, 1996.
Ping et al., “Altered β-adrenergic receptor signaling in heart failure, in vivo gene transfer via adeno and adeno-associated virus, ”Microcirculation, 3:225-228, 1996.
Akiyama et al., “Genistein, a specific inhibitor of tyrosine-specific protein kinases,”J. Biol. Chem., 262(12):5592-5595, 1987.
Alexander et al., “Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors,”Hum. Gene Ther., 7:841-850, 1996.
Berns and Bohenzky, “Adeno-Associated Viruses: An Update,”Adv. Virus Res., 32:243-307, 1987.
Berns and Giraud, “Adeno-Associated Virus (AAV) Vectors in Gene Therapy: Biology of Adeno-Associated Virus,”Curr. Top. Microbiol. Immunol., 218:1-23, 1996.
Bertran et al., “Recombinant Adeno-Associated Virus-Mediated High-Efficiency, Transient Expression of the Murine Cationic Amino Acid Transporter (Ecotropic Retroviral Receptor) Permits Stable Transduction of Human HeLa Cells by Ecotropic Retroviral Vectors,”J. Virol., 70 (10) 6759-6766, 1996.
Boonstra et al., “The Epidermal Growth Factor,”Cell Biol. Intl., 19:413-430, 1995.
Carlo-Stella et al., “Effect of the Protein Tyrosine Kinase Inhibitor Genistein on Normal and Leukaemic Haemopoietic Progenitor Cells,”Br. J. Haematol., 93:551-557, 1996.
Carter and Flotte, “Adeno-Associated Virus (AAV) Vectors in Gene Therapy: Development of Adeno-Associated Virus Vectors for Gene Therapy of Cystic Fibrosis,”Curr. Top. Microbiol. Immunol., 218:119-144, 1996.
Chatterjee and Wong Jr., “Adeno-Associated Virus (AAV) Vectors in Gene Therapy: Adeno-Associated Virus Vectors for Gene Therapy of the Hematopoietic System,”Curr. Top. Microbiol. Immunol., 218:61-73, 1996.
Chatterjee et al., “Strategies for efficient gene transfer into hematopoietic cells: The use of adeno-associated virus vectors in gene therapy,”Ann. N.Y. Acad. Sci., 770:79-90, 1995.
Constantinou and Huberman, “Genistein as an Inducer of Tumor Cell Differentiation: Possible Mechanisms of Action,”Soc. Exp. Biol. Med., 208:109-115, 1995.
Couldwell et al., “Protein Kinase C Inhibitors Induce Apoptosis in Human Malignant Glioma Cell Lines,”FEBS Lett., 345:43-46, 1994.
Dudek et al., “Regulation of neruonal survival by the serine-threonine protein kinase Akt,”Science, 275:661-664, 1996.
Faaland et al., “Rapid Uptake of Tyrphostin into A431 Human Epidermoid Cells Is Followed by Delayed Inhibition of Epidermal Growth Factor (EGF)-Stimulated EGF Receptor Tyrosine Kinase Activity,”Mol. Cell Biol., 11(5):2697-2703, 1991.
Fabricant et al., “Nerve Growth Factor Receptors on Human Melanoma Cells in Culture,”Proc. Natl. Acad. Sci. USA, 74:565-569, 1977.
Ferrari et al., “Second-strand synthesis is a rate-limiting step for efficient transduction by recombination adeno-associated virus vectors,”J. Virol.,70(5):3227-3234, 1996.
Fisher et al., “Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy,”Nat. Med.,3:306-312, 1997.
Fisher et al., “Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis,”J. Virol.,70:520-532, 1996.
Flotte et al., “Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus victor,”Proc. Natl. Acad. Sci. USA,90:10613-10617, 1993.
Fukazawa et al., “Specific Inhibition of Cytoplasmic Protein Tyrosine Kinases by Herbimycin A In Vitro,”Biochem. Pharmacol.,42:1661-1671, 1991.
Gamou et al., “Molecular Evidence for the Lack of Epidermal Growth Factor Receptor Gene Expression in Small Cell Lung Carcinoma Cells,”Cancer Res.,47:2668-2673, 1987.
Gazit et al., “Tyrphostins I: Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors,”J. Med. Chem.,32:2344-2352, 1989.
Ghiringhelli and Romanowski, “Quick Methylene Blue Staining for Visualizing Virus Plaques in Titration Experiments,”Biotechniques,17:464-465, 1994.
Giard et al., “In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived from a Series of Solid Tumors,”J. Natl. Cancer Inst.,51:1417-1423, 1973.
Goodman et al., “Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells,”Blood,84(5):1492-1500, 1994.
Kaplitt et al., “Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain,”Nat. Genet.,8:148-153, 1994.
Kessler et al., “Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein,”Proc. Natl. Acad. Sci. USA,93:14082-14087, 1996.
Koeberl et al., “Persistent Expression of Human Clotting Factor IX from Mouse Liver After Intravenous Injection of Adeno-Associated Virus Vectors,”Proc. Natl. Acad. Sci. USA,94:1426-1431, 1997.
Kotin et al., “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,”Human Gene Therapy,5:793-801, 1994.
Kotin et al., “Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter,”Genomics,10:831-834, 1991.
Kotin et al., “Site-specific integration by adeno-associated virus,”Proc. Natl. Acad. Sci. USA,87:2211-2215, 1990.
Kube and Srivastava, “Quantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions,”Nucl. Acids Res.,25(16):3375-3376, 1997.
Kube et al., “Encapsidation of adeno-associated virus type 2 rep proteins in wild-type and recombin
Bajpai Anil
Ponnazhagan Selvarangan
Qing Keyun
Srivastava Arun
Wang Xu-Shan
Advanced Research & Technology Institute
Fulbright & Jaworski
Guzo David
LandOfFree
Role of tyrosine phosphorylation of a cellular protein in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Role of tyrosine phosphorylation of a cellular protein in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Role of tyrosine phosphorylation of a cellular protein in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3617068